# Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults

> **NCT02224560** · PHASE3 · COMPLETED · sponsor: **Jazz Pharmaceuticals** · enrollment: 225 (actual)

## Conditions studied

- Epilepsy
- Lennox Gastaut Syndrome

## Interventions

- **DRUG:** GWP42003-P
- **DRUG:** Placebo control

## Key facts

- **NCT ID:** NCT02224560
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-08
- **Primary completion:** 2016-05-19
- **Final completion:** 2016-05-19
- **Target enrollment:** 225 (ACTUAL)
- **Last updated:** 2022-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02224560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02224560, "Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02224560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*